Abstract
High-grade glioma continues to be one of the prevalent diseases linked to an unfavorable outcome. Therefore, it is of interest to investigate the prognostic value of reoperation in patients with recurrent glioblastoma. The sample size was divided into two subcategories solely in order to assess the effectiveness of a second surgery at glioblastoma advancement: (a) study participants who undergone re-resection usually accompanied by systematic therapy and (b) participants who received extra chemotherapy. The median overall survival (OS) was 26 months among the individuals who underwent re-surgery as opposed to 18 months in the nonsurgical category. Progression-free survival (PFS) varied considerably between re-surgery (thirteen months) vs. non-surgical (ten months) groups. Comparing the group receiving re-surgery (ten months) and the group receiving only systemic therapy (nine months), the median post-progression survival (PPS), did not change substantially. Our second procedure complication rate was under acceptable ranges and consistent with earlier reports. Despite good clinical outcomes in patients who underwent reoperation, we were unable to show survival advantages.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
